Nogués Martín A, Varela Francisco J, Seminario Gisela, Insúa María C, Bezrodnik Liliana
Instituto de Investigaciones Neurológicas Raúl Carrea (FLENI), Buenos Aires, Argentina. E-mail:
Medicina (B Aires). 2016;76(1):36-9.
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an acquired disease that may affect nerve roots and peripheral nerves. Despite its low incidence, diagnosis is particularly important because there are different effective treatments. Human immunoglobulin is one of the mainstays of the treatment. Although there are few studies up to date, subcutaneous immunoglobulin (IgSC) has been proposed as an alternative to intravenous administration with similar efficacy. We present three cases with definite CIDP, classified according to the European Federation of Neurological Societies / Peripheral Nerve, Society (EFNS /PNS) criteria in which was used SCIgG as a treatment after success with the intravenous route. The Overall Neuropathy Limitations Scale (ONLS) was used to estimate the changes in the muscular strength before and after treatment.
慢性炎症性脱髓鞘性多发性神经根神经病（CIDP）是一种可能影响神经根和周围神经的后天性疾病。尽管其发病率较低，但诊断尤为重要，因为有不同的有效治疗方法。人免疫球蛋白是主要治疗手段之一。虽然目前相关研究较少，但皮下免疫球蛋白（IgSC）已被提议作为静脉给药的替代方法，且疗效相似。我们报告3例确诊为CIDP的病例，根据欧洲神经病学学会联合会/周围神经学会（EFNS/PNS）标准分类，这些病例在静脉途径治疗成功后使用皮下注射免疫球蛋白（SCIgG）进行治疗。采用总体神经病变限制量表（ONLS）评估治疗前后肌肉力量的变化。
